Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Lundbeck Files Anti-CGRP Antibody Eptinezumab in Japan
November 18, 2025
- Nipro Files for Full Approval of Stemirac Cell Therapy
November 18, 2025
- Dupixent 200 mg Pen Now Available in Japan: Sanofi
November 18, 2025
- Maruho Licenses Antibiotic Faropenem to China’s CR Gosun
November 18, 2025
- Otsuka/Ionis’ HAE Prevention Drug Wins CHMP Backing
November 18, 2025
- Japan’s Big 4 Wholesalers Lower Operating Margin as COVID-19 Windfall Recedes
November 18, 2025
- Fuji Stresses No Supply Impact, Denies Patent Allegations over Eylea Biosimilar
November 17, 2025
- Kura, Kyowa Kirin Land US FDA Approval for AML Med Komzifti
November 17, 2025
- Novartis Overhauls Sales Model to Prioritize Solving Regional Treatment Gaps
November 14, 2025
- Keytruda Again Tops Japan Market in July-September: IQVIA
November 14, 2025
- UK Clears Monthly IV Maintenance Dosing for Leqembi: Eisai/Biogen
November 14, 2025
- Kaken Gets Select-Asia Rights to Numab’s Multi-Specific Antibody
November 14, 2025
- Pluvicto, Imaavy, Hernexeos Now Available in Japan
November 13, 2025
- Meiji, NCC Launch Research on Self-Amplifying mRNA Cancer Vaccine
November 13, 2025
- Bayer, Regeneron Move to Block Fuji’s Newly Listed Eylea Biosimilar in Japan
November 13, 2025
- J&J Japan Targets Top Share in Key Disease Areas by 2030: New President
November 12, 2025
- Biogen Launches Higher-Dose Spinraza in Japan
November 12, 2025
- Meiji Pharma to Set Up Singapore Subsidiary to Drive ASEAN Biz
November 12, 2025
- Alfresa Deepens Tie-Up with China Wholesaler to Support Japan-to-China Licensing
November 12, 2025
- Japan’s Generic, Biosimilar Market Seen Topping 2 Trillion Yen in 2033: Fuji Keizai
November 12, 2025
ページ
Japan is opening a new chapter in sleep medicine. The recent decision to allow medical institutions to advertise “sleep disorders”…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…